Sucampo Pharma Europe Presents Long-Term Safety and Efficacy Data of Lubiprostone in Chronic Idiopathic Constipation
10/21/2008 9:16:20 AM
BETHESDA, MD & OXFORD, UK--(BUSINESS WIRE)--Sucampo Pharma Europe, Ltd., a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), today announced the results from three open-labeled, long-term (6 and 12 months) clinical trials of lubiprostone (AMITIZA®). These trials were conducted between November 2001 and January 2005 and the results were previously reported in the United States. These data demonstrate that lubiprostone provided significant improvements in subjective assessments of symptoms and was well tolerated in patients with Chronic Idiopathic Constipation (CIC). Statistically significant improvements in subjective assessments were seen in secondary endpoints including constipation severity, abdominal bloating and abdominal discomfort.
comments powered by